Skip Navigation
  Search Menu
Find an Expert


Ravit Boger, M.D.

Photo of Dr. Ravit Boger, M.D.

Professor of Pediatrics


Expertise: Infectious Diseases, Pediatric Infectious Disease

Research Interests: Congneital Cytomegalovirus infection; Viral load; Genotyping; Strain diversity


Johns Hopkins Pediatrics
Appointment Phone: 410-614-3917

200 N. Wolfe Street
Rubenstein Child Health Building
Baltimore, MD 21287 map
Phone: 410-614-3917
Fax: 410-614-1491


Dr. Ravit Boger is an associate professor of pediatrics and oncology at the Johns Hopkins University School of Medicine. Her area of clinical expertise is pediatric infectious diseases.

She is known for her research on congenital cytomegalovirus (CMV) infection. Her lab was among the first in this country to characterize CMV genes, and they recently identified a protein that regulates the body’s immune response to CMV.

Dr. Boger earned her medical degree from the Sackler School of Medicine at Tel-Aviv University. Following an internship at the Rabin Medical Center in Petah-Tivah, Israel, and service as a physician in the Israel Defense Forces, she completed a residency in pediatrics at Dana Children’s Hospital in Tel-Aviv. Dr. Boger performed her fellowship in pediatric infectious diseases at Johns Hopkins University School of Medicine. She joined the Johns Hopkins faculty in 2001. Since April 2006, she has been a preceptor in the Harriet Lane Clinic, Hopkins Children’s community clinic for children and adolescents.

Her research interests include CMV infection, with a particular focus of identifying and developing novel anti-CMV compounds. Her studies also focus on understanding the mechanisms of CMV inhibition by newly identified anti-CMV compounds.

She is a member of the American Society of Pediatric Infectious Diseases and the Infectious Diseases Society of America. more


  • Professor of Pediatrics
  • Professor of Oncology



  • M.D., Tel Aviv University - Sackler Fac of Medicine - Tel Aviv - (Israel) (1989)

Research & Publications

Research Summary

Dr. Ravit's research focuses on characterizing CMV strains and understanding their impact on pathogenesis and outcome of congenital CMV infection. In addition, her laboratory is actively involved in research of novel compounds for CMV therapy.

Her work is funded by the NIH and has been published in several research journals. Dr. Boger is a member of the collaborative anti-viral study group and is a site principal investigator for a clinical trial of valganciclovir in congenital CMV infection.


Dr. Boger's laboratory is working on the identification and development of novel anti-Cytomegalovirus compounds. Their studies also focus on understanding the mechanisms of CMV inhibition by newly identified anti-CMV compounds.

Main research topics in the laboratory include:

  • CMV inhibition by artemisinin-derived dimers
  • Models of anti-viral combination therapy
  • Role of WNT pathway in CMV replication
  • CMV recognition by NOD2

Lab Website: Boger CMV Lab

Clinical Trial Keywords


Clinical Trials

Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection (Gan Premie)

Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating with Valganciclovir Therapy

Selected Publications

Kapoor A, Forman M, Arav-Boger R. "Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication." PLoS One. 2014 Mar 26;9(3):e92704. doi: 10.1371/journal.pone.0092704. eCollection 2014.

Cai H, Kapoor A, He R, Venkatadri R, Forman M, Posner GH, Arav-Boger R. "In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action." Antimicrob Agents Chemother. 2014 Feb;58(2):986-94. doi: 10.1128/AAC.01972-13. Epub 2013 Nov 25.

He R, Forman M, Mott BT, Venkatadri R, Posner GH, Arav-Boger R. "Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety." Antimicrob Agents Chemother. 2013 Sep;57(9):4208-14. doi: 10.1128/AAC.00893-13. Epub 2013 Jun 17.

Mott BT, He R, Chen X, Fox JM, Civin CI, Arav-Boger R, Posner GH. "Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: a structure-activity study." Bioorg Med Chem. 2013 Jul 1;21(13):3702-7. doi: 10.1016/j.bmc.2013.04.027. Epub 2013 Apr 22.

Kapoor A, He R, Venkatadri R, Forman M, Arav-Boger R. "WNT modulating agents inhibit human cytomegalovirus replication." Antimicrob Agents Chemother. 2013 Jun;57(6):2761-7. doi: 10.1128/AAC.00029-13. Epub 2013 Apr 9.

Activities & Honors


  • Recognition, Thomas Wilson Foundation, 2005 - 2006
  • Clinician Scientist Award, Johns Hopkins University School of Medicine, 2003 - 2005
  • Recognition, United Cerebral Palsy, 2003 - 2005


  • American Society of Pediatric Infectious Diseases
  • Infectious Diseases Society of America
Is this you? Edit Profile